Business Wire

TX-PLANVIEW

18.5.2022 15:02:10 CEST | Business Wire | Press release

Share
Planview Announces Strategic Acquisition of Tasktop

Planview, a global leader in Portfolio Management and Work Management, today announced that the company has entered into a definitive agreement to acquire Tasktop, a pioneer and leader in Value Stream Management (VSM). Based in Vancouver, Canada, Tasktop has 200+ employees and in FY21 saw record growth with 43% year-over-year user expansion.

“As companies strive to differentiate, survive, thrive, and disrupt their markets, there is a surge in digitalization and transformation initiatives. While well-intended, the facts show that most digital transformation efforts fail to achieve value for the business,” said Razat Gaurav, Chief Executive Officer at Planview. “Together, we provide an exciting and much needed capability that will help our customers to connect the business of software delivery – enabling them to efficiently transform their organizations faster with more confidence, and a better ability to achieve desired business outcomes.”

“Connecting Planview’s leadership in enterprise Agile and strategic portfolio management with Tasktop’s leadership in VSM is a game-changing combination that expands the capabilities and value proposition we can offer to customers. Tasktop and Planview’s complementary offerings will better help our customers realize digital transformation – accelerating the pace at which they can transform and deliver competitive advantages through technology,” said Mik Kersten, Founder and Chief Executive Officer at Tasktop. “Tasktop and Planview have more than eight years of history working together, and we’re thrilled to be taking this next step in our relationship to join forces and make it possible for every organization to become a digital innovator.”

The acquisition of Tasktop is part of Planview’s strategy to build the future of connected work and deliver transformative solutions. Together, Planview and Tasktop will empower organizations to accelerate their time to market, improve operational efficiency and drive investment confidence in the face of economic disruption and instability. In the past year, Tasktop’s solutions have played a critical part of some of the world’s most successful digital transformations, including BMW, HSBC, Kaiser Permanente, T-Mobile and TUI Group. Similarly, Planview has added marquee global customers such as ADP, AT&T, IBM, FIFA, and Standard Chartered.

Leading industry analyst firms like Forrester1 point to the benefits of integrating Strategic Portfolio Management (SPM) and VSM. According to Forrester, “Building genuine business agility requires having the necessary information at hand to make pivot or persevere decisions. When SPM is integrated with delivery systems such as value stream management (VSM), it provides visibility into actual performance to support change decisions.”1

Upon completion of the transaction, the Tasktop team will join Planview, bringing additional expertise and thought leadership around VSM. Kersten will serve as Chief Technology Officer. The transaction is expected to close mid-Summer of 2022, pending regulatory approval. Terms of the transaction were not disclosed.

1 Forrester, Now Tech: Strategic Portfolio Management Tools, Q3 2021, Margo Visitacion, August 19, 2021.

About Planview

Planview has one mission: to build the future of connected work. Our solutions enable organizations to connect the business from ideas to impact, empowering companies to accelerate the achievement of what matters most. Planview’s full spectrum of Portfolio Management and Work Management solutions creates an organizational focus on the strategic outcomes that matter and empowers teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enables customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, with locations around the world, Planview has more than 1,000 employees supporting 4,000 customers and 2.4 million users worldwide. For more information, visit www.planview.com .

About Tasktop

Tasktop's value stream management platform enables enterprises to master software at scale. Leading brands, including half of the Fortune 100, use Tasktop to provide real-time visibility into the health of product value streams, allowing them to make better decisions and align with business goals. Tasktop connects with existing third party tools businesses are already using and overlays the end-to-end value stream to provide the abstractions, automations, visualizations and forensics needed to practice value stream management on a daily basis. Learn more about Tasktop at tasktop.com and follow us on Twitter @tasktop.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye